Brief: Revive Therapeutics Submits Updated Briefing Package
19/01/2023 21:52
Jan 19 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS SUBMITS UPDATED BRIEFING PACKAGE IN
SUPPORT
OF UPCOMING TYPE C MEETING GRANTED BY FDA FOR AMENDED PROTOCOL
AGREEMENT OF PHASE 3 CLINICAL STUDY FOR BUCILLAMINE IN THE
TREATMENT OF COVID-19
* REVIVE THERAPEUTICS LTD - GOAL DATE FOR FDA TO PROVIDE ITS
WRITTEN RESPONSES IS MARCH 7, 2023
* REVIVE - IF FDA AGREE WITH PROPOSED PRIMARY, SECONDARY
ENDPOINTS
OR A VERSION FDA RECOMMENDS, WILL INCORPORATE ENDPOINTS INTO
AMENDED STUDY PROTOCOL
Source text for Eikon: ID:nGNX3jvdLc
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure